Table 1.

Clinical and demographic characteristics.

	SLE aPS/PT positive		SLE aPS/PT negative
	(N = 18)	%	(N = 34)	%
Age
Years (mean ±SD)	47.5 ± 11.5		44.8 ± 13.5
Female
(N; %)	14	77.8	28	82.4
aPS/PT IgG
Positive (N; %)	11	61.1
Titer (mean ±SD; median [range])	99.8 ± 77.8; 121 [12–229]
aPS/PT IgM
Positive (N; %)	16	88.9
Titer (mean ±SD; median [range])	126.2 ± 150.8; 131 [8–518]
Lupus anti-coagulant
Positive (N; %)	5	27.8	12	35.3
SLE manifestation
Skin (N; %)	6	33.3	8	23.5
Joints (N; %)	17	94.4	28	82.4
Hematological (N; %)	3	16.7	6	17.6
Lupus Nephritis* (N; %)	8	44.4	11	32.4
Sierositis (N; %)	4	22.2	7	20.6
Follow-up**
Years (mean ±SD; median [range])	3.7 ± 1.2		3.9 ± 1.1
SLE disease duration
Years (mean ±SD; median [range])	15.7 ± 8.1		19.7 ± 7.2
Therapy**
Hydroxychloroquine (N; %)	17	94.4	33	97.1
Prednisone <7.5 mg/die*** (N; %)	14	77.8	22	64.7
Cyclophosphamide (N; %)	2	11.1	2	5.9
Mycophenolate (N; %)	3	16.7	3	8.8
Azathioprine (N; %)	6	33.3	10	29.4
Methotrexate (N; %)	3	16.7	5	14.7
Rituximab (N; %)	5	27.8	10	29.4
Belimumab (N; %)	3	16.7	5	14.7
Thrombotic risk factors
Arterial hypertension (N; %)	7	38.9	10	29.4
Hyperlipidemia (N; %)	2	11.1	5	14.7
Smoking habit (N; %)	3	16.7	5	14.7
Diabetes (N; %)	0	0.0	0	0.0
Hormone replacement therapy (N; %)	0	0.0	0	0.0
Inherited thrombophilia (N; %)	0	0.0	0	0.0

^*Biopsy-proven.

^**After aPS/PT testing.

^***For at least 80% of the observation time.

No statistical difference was observed between the two groups.

S.D., standard deviation; N., number; aPS/PT, anti-phosphatidylserine/prothrombin; Ig, immunoglobulins; SLE, Systemic Lupus Erythematosus.